The PARP inhibitor market size is expected to reach USD 6.28 billion in 2024, at a CAGR of 8.70% through 2034. The industry value is likely to reach USD 16.15 billion by 2034. Among the major drivers of the increased use of PARP inhibitors are more regulations on who can get them in cases where ovarian, prostate, and breast cancers have been diagnosed.
The proven efficiencies of PARP inhibitors on the improvement of progression-free survival (PFS) and overall survival (OS) in their clinical trials continue driving demand for these drugs by oncologists and patients who are on a quest for better treatment options.
Pharma companies developing and launching PARP inhibitors have added new wings to their clinical trial activities, which intend to measure new indicants for their drug and, thereby, their regulatory pathway. Significant investments are made into biotech companies by many pharma companies to study the efficacy of pooled PARP inhibitors in more cancer types.
The most helpful effect of PARP inhibitors is shown in those mutations when subjected to BRCA1/2 amidst other mutations in the patient's genome. The recent rise of precision medicine and genetic testing technologies has, to a certain extent, eased the identification process of patient eligibility - candidates likely to derive maximum benefit from PARP inhibitor therapy. As such, patient stratification in advance of treatment with PARP inhibitors is increasingly gaining prominence for biomarker testing.
Leading pharmaceutical companies are collaborating with diagnostic companies to develop companion diagnostic tests that could accurately identify the biomarkers predictive of response towards PARP inhibitors. This is done as a result of providing important and wide-ranging testing solutions targeted at bettering the practice of the use of PARP inhibitors by providing effective ways of selecting patients and, hence, providing good treatment outcomes.
| Attributes | Details |
|---|---|
| PARP Inhibitor Market Value for 2024 | USD 6.28 billion |
| PARP Inhibitor Market Value for 2034 | USD 16.15 billion |
| PARP Inhibitor Market Forecast CAGR for 2024 to 2034 | 8.70% |
Expansion into Rare Cancers
An interesting development that is rising in the industry is the expansion into relatively broader markets, like ovarian and breast cancer, through applications into rare cancers. One of the novelties that have consequently come out is the potential of PARP inhibitors in rare lines of cancer. Therefore, companies are investing in clinical trials to ensure there are no unmet medical needs for the varying types of cancer and PARP products.
Combination Therapies
PARP inhibitor manufacturers are now looking into combination modalities with other treatment modes, whether they be immunotherapy, targeted therapy, or chemotherapies. Preclinical and clinical studies so far have been rather optimistic about the combination of PARP inhibitors with other drugs, showing synergy of effects and an improved treatment outcome.
Such trends, therefore, enunciate the change toward multimodal approaches to oncology treatment approaches and a certain willingness to allow PARP inhibitors into combination regimens for more efficacy.
Biomarker-driven Therapies
Evolving genomic testing techniques and precision medicine have shifted the focus toward biomarker-driven treatment in the PARP inhibitor market. As such, several companion diagnostic tests have been developed by pharmaceutical companies to pinpoint genetic mutations or biomarkers in patients who are most likely to benefit from therapy with a PARP inhibitor. Such a move shows how important personalized medicine is in optimizing treatment outcomes and the clinical utility of drugs like PARP inhibitors.
Indication Expansion
The most common trend emerging with the highest impact is indication expansion, which is likely to drive PARP inhibitor adoption beyond BRCA-mutated cancers. Recent approvals and ongoing clinical trials for PARP inhibitors include patients with cancers, especially those with homologous recombination deficiency (HRD) or other DNA repair defects, regardless of BRCA mutation status.
This broader pool of patients provides a massive market opportunity for PARP inhibitors and provides interesting insights into the potential utility of these drugs across different kinds of cancer.
This section provides detailed insights into specific segments in the PARP inhibitor industry.
| By Drug Type | Olaparib |
|---|---|
| Market Share in 2024 | 86.20% |
Olaparib dominates the PARP inhibitor sector, owning an 86.2% share in 2024.
Being the first ever regulatory-approved PARP inhibitor, Olaparib has become a well-known and widely accepted treatment option. With more indications authorized than any other PARP inhibitors, Olaparib is flexible enough to be used as a remedy for different types of cancer. The significant number of clinical data establishes Olaparib’s efficacy against certain cancer cases, thus strengthening its position as the main therapeutic modality.
Positive policies on reimbursements in some areas enhance accessibility to patients who require it most, thus increasing its share value further.
| By Indication | Ovarian Cancer |
|---|---|
| Market Share in 2024 | 83.90% |
By indication, the ovarian cancer segment leads with an 83.9% market share in 2024.
Ovarian cancer is one of the most common gynecologic malignancies hence a large population of patients looking for effective therapy. This makes PARP inhibitors an ideal choice for many people since they have proved to be highly efficient in curing various types of ovarian cancer.
Traditionally; there are just very limited historical treatments available for ovarian cancer; however, the introduction of PARP inhibitors provides a new and effective approach, leading to growth in this segment of the market.
Raising awareness about PARP inhibitors among patients and healthcare professionals is resulting in broader acceptance of these treatments for ovarian cancer.
This section identifies key countries where the PARP inhibitor market is concentrated such as the United States, United Kingdom, China, Japan, and South Korea. It also highlights lucrative opportunities and trends driving the demand for PARP inhibitors in each.
| Countries | CAGR |
|---|---|
| United States | 1.20% |
| United Kingdom | 5.10% |
| China | 3.40% |
| Japan | 1.60% |
| South Korea | 2.80% |
PARP inhibitor industry in the United States is projected to grow at a rate of 1.20% by 2034.
The healthcare system of the United States, through its personalized medicine approaches, has sufficiently been adapted to the targeted nature of PARP inhibitor therapies. The United States has been a pacesetter in driving research and development for pharmaceuticals, hence encouraging innovation within the PARP inhibitor marketplace.
The high prevalence of cancer in the United States creates a large patient population for PARP inhibitor treatment. While strict regulatory processes may tend to be barriers to the market, on the other side, it is also true that the intensity of these processes assures safety and effectiveness for the PARP inhibitors.
The United Kingdom's PARP inhibitor industry is anticipated to expand at a CAGR of 5.1% through 2034. The United Kingdom has a very well-established, leading healthcare system that supports and means there is excellent access to new treatments - like PARP inhibitors. The awareness of PARP inhibitors is set to grow among patients and healthcare professionals, which would translate to a boost in demand and market growth in the UK.
Accordingly, the Government of the United Kingdom has followed suit by dramatically drawing reimbursement policies for PARP inhibitor therapies to be more widely available to sections of patients. The United Kingdom healthcare system underlines the importance of catching cancer in its early stages to ensure a larger pool of customers for the PARP inhibitor.
This relatively creates a favorable condition for new emerging PARP inhibitor drugs because it guarantees faster drug approval and thereby expands market support.
China's PARP inhibitor market is poised to expand at a CAGR of 3.4% through 2034.
Growing disposable incomes in China have allowed patients to increasingly welcome pricier, state-of-the-art therapy lines like those provided by PARP inhibitors. The Chinese government is guiding future innovations and putting out new treatments for cancer, which include PARP inhibitors.
The increasing incidence of cancer in China creates a substantial patient pool for PARP inhibitor therapies. China's name is also on the list of developing and enhancing healthcare infrastructure to make sure that specializations for cancer are also available to its citizens.
Besides, the government encourages the import reliance of policies towards more domestic production of the PARP inhibitors.
Japan's PARP inhibitor industry is projected to rise at a moderate CAGR of 1.60% through 2034.
The key regulatory framework for drug approval must adhere strictly to ensuring that there is proper evaluation of PARP inhibitors before the drug enters the market.
Also gaining prominence in the Japanese health system is a new class of drugs that pays more attention and is heavily influenced by the cost-effective treatment: PARP inhibitors.
A strong standard of care in certain cancers may temper the speed of PARP inhibitor uptake at times. Therefore, the aging population in Japan will likely produce a huge pool in line for cancer treatment, which may yield a driving force behind the demand for PARP inhibitors in the long run.
Japan has a solid healthcare technology infrastructure that cuts across first-class services to bring into place potential integration and much more use than PARP inhibitor therapy offers.
South Korea's PARP inhibitor market is expected to rise at a 2.80% CAGR through 2034.
The government has shown active support for innovative development and access to treatment of cancer, including treatment development in the case of PARP inhibitors. The increased awareness of cancer is causing people to get early detection and be amenable to accepting new state-of-the-art treatments.
The healthcare system in South Korea is evolving towards an increased focus on early identification and treatment of cancer, potentially expanding the population who could benefit from PARP inhibitor therapy. Another very relevant factor is the aging population, which probably reinforces the use of PARP inhibitors in some patient cases.
The country's strong focus on technological innovation prepares South Korea well for the adaption and integration of new developments in the PARP inhibitor field.
The PARP inhibitor market is very dynamic, where established pharmaceutical behemoths and innovative start-ups are jostling for space. Names like AstraZeneca, AbbVie, and Merck are on the front line of this charge. These companies use their strong R&D departments, ample clinical trial data, and mature global marketing networks to stay in their dominant positions with PARP inhibitors such as Lynparza and Olaparib.
Nevertheless, these players are not unchallenged. There is a new breed of nimble startups that bring speed and focus to the challenger round. Such firms have a specific aim at targeting areas like next-generation PARP inhibitors with better potency or those focused on certain cancer types. They have disruptive potential because they can introduce new therapies which may have significant impacts on the market.
Recent Developments in the PARP Inhibitor Industry
| Report Attributes | Details |
|---|---|
| Current Total Market Size (2024) | USD 6.28 billion |
| Projected Market Size (2034) | USD 16.15 billion |
| CAGR (2024 to 2034) | 8.70% |
| Base Year for Estimation | 2023 |
| Historical Period | 2019 to 2023 |
| Projections Period | 2024 to 2034 |
| Market Analysis Parameters | Revenue in USD billion |
| By Drug Type | Olaparib, Niraparib, Rucaparib, Talazoparib |
| By Indication | Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| Regions Covered | North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, Middle East and Africa |
| Countries Covered | United States, Japan, Germany, India, United Kingdom, France, Italy, Brazil, Canada, South Korea, Australia, Spain, Netherlands, Saudi Arabia, Switzerland |
| Key Players | AstraZeneca, GlaxoSmithKline plc, AbbVie Inc, Merck Co. & Inc, Clovis Oncology, Johnson & Johnson Services, Inc, Pfizer Inc., Genentech, Inc., Artios Pharma, Sierra Oncology, Inc., Karyopharm Therapeutics Inc. |
| Additional Attributes | Dollar sales by value, market share analysis by region, country-wise analysis. |
| Customization and Pricing | Available upon request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034
Table 2: Global Market Volume (Unit Pack) Forecast by Region, 2019 to 2034
Table 3: Global Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 4: Global Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 5: Global Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 6: Global Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 7: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 8: Global Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 9: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 10: North America Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 11: North America Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 12: North America Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 13: North America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 14: North America Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 15: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 16: North America Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 17: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 18: Latin America Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 19: Latin America Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 20: Latin America Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 21: Latin America Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 22: Latin America Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 23: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 24: Latin America Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 25: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 26: Western Europe Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 27: Western Europe Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 28: Western Europe Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 29: Western Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 30: Western Europe Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 31: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 32: Western Europe Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 33: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 34: Eastern Europe Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 35: Eastern Europe Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 36: Eastern Europe Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 37: Eastern Europe Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 38: Eastern Europe Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 39: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 40: Eastern Europe Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 41: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 42: South Asia and Pacific Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 43: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 44: South Asia and Pacific Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 45: South Asia and Pacific Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 46: South Asia and Pacific Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 47: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 48: South Asia and Pacific Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 49: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 50: East Asia Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 51: East Asia Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 52: East Asia Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 53: East Asia Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 54: East Asia Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 55: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 56: East Asia Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Table 57: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034
Table 58: Middle East and Africa Market Volume (Unit Pack) Forecast by Country, 2019 to 2034
Table 59: Middle East and Africa Market Value (US$ Million) Forecast by Drug Type, 2019 to 2034
Table 60: Middle East and Africa Market Volume (Unit Pack) Forecast by Drug Type, 2019 to 2034
Table 61: Middle East and Africa Market Value (US$ Million) Forecast by Indication, 2019 to 2034
Table 62: Middle East and Africa Market Volume (Unit Pack) Forecast by Indication, 2019 to 2034
Table 63: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Table 64: Middle East and Africa Market Volume (Unit Pack) Forecast by Distribution Channel, 2019 to 2034
Figure 1: Global Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 2: Global Market Value (US$ Million) by Indication, 2024 to 2034
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 4: Global Market Value (US$ Million) by Region, 2024 to 2034
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034
Figure 6: Global Market Volume (Unit Pack) Analysis by Region, 2019 to 2034
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034
Figure 9: Global Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 10: Global Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 11: Global Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 12: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 13: Global Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 14: Global Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 15: Global Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 16: Global Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 17: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 18: Global Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 21: Global Market Attractiveness by Drug Type, 2024 to 2034
Figure 22: Global Market Attractiveness by Indication, 2024 to 2034
Figure 23: Global Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 24: Global Market Attractiveness by Region, 2024 to 2034
Figure 25: North America Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 26: North America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 27: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 28: North America Market Value (US$ Million) by Country, 2024 to 2034
Figure 29: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 30: North America Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 31: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 32: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 33: North America Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 34: North America Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 37: North America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 38: North America Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 39: North America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 40: North America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 41: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 42: North America Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 43: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 44: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 45: North America Market Attractiveness by Drug Type, 2024 to 2034
Figure 46: North America Market Attractiveness by Indication, 2024 to 2034
Figure 47: North America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 48: North America Market Attractiveness by Country, 2024 to 2034
Figure 49: Latin America Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 50: Latin America Market Value (US$ Million) by Indication, 2024 to 2034
Figure 51: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 52: Latin America Market Value (US$ Million) by Country, 2024 to 2034
Figure 53: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 54: Latin America Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 57: Latin America Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 58: Latin America Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 59: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 60: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 61: Latin America Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 62: Latin America Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 65: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 66: Latin America Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 67: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 68: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 69: Latin America Market Attractiveness by Drug Type, 2024 to 2034
Figure 70: Latin America Market Attractiveness by Indication, 2024 to 2034
Figure 71: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 72: Latin America Market Attractiveness by Country, 2024 to 2034
Figure 73: Western Europe Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 74: Western Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 75: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 76: Western Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 77: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 78: Western Europe Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 79: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 80: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 81: Western Europe Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 82: Western Europe Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 83: Western Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 84: Western Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 85: Western Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 86: Western Europe Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 87: Western Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 88: Western Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 89: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 90: Western Europe Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 93: Western Europe Market Attractiveness by Drug Type, 2024 to 2034
Figure 94: Western Europe Market Attractiveness by Indication, 2024 to 2034
Figure 95: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 96: Western Europe Market Attractiveness by Country, 2024 to 2034
Figure 97: Eastern Europe Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 98: Eastern Europe Market Value (US$ Million) by Indication, 2024 to 2034
Figure 99: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 100: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034
Figure 101: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 102: Eastern Europe Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 103: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 104: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 105: Eastern Europe Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 106: Eastern Europe Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 110: Eastern Europe Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 111: Eastern Europe Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 112: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 113: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 114: Eastern Europe Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 115: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 116: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 117: Eastern Europe Market Attractiveness by Drug Type, 2024 to 2034
Figure 118: Eastern Europe Market Attractiveness by Indication, 2024 to 2034
Figure 119: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 120: Eastern Europe Market Attractiveness by Country, 2024 to 2034
Figure 121: South Asia and Pacific Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 122: South Asia and Pacific Market Value (US$ Million) by Indication, 2024 to 2034
Figure 123: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 124: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034
Figure 125: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 126: South Asia and Pacific Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 127: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 128: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 129: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 130: South Asia and Pacific Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 131: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 132: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 133: South Asia and Pacific Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 134: South Asia and Pacific Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 135: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 136: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 137: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 138: South Asia and Pacific Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 139: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 140: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 141: South Asia and Pacific Market Attractiveness by Drug Type, 2024 to 2034
Figure 142: South Asia and Pacific Market Attractiveness by Indication, 2024 to 2034
Figure 143: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 144: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034
Figure 145: East Asia Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 146: East Asia Market Value (US$ Million) by Indication, 2024 to 2034
Figure 147: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 148: East Asia Market Value (US$ Million) by Country, 2024 to 2034
Figure 149: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 150: East Asia Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 151: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 152: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 153: East Asia Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 154: East Asia Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 155: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 156: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 157: East Asia Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 158: East Asia Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 159: East Asia Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 160: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 161: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 162: East Asia Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 163: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 164: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 165: East Asia Market Attractiveness by Drug Type, 2024 to 2034
Figure 166: East Asia Market Attractiveness by Indication, 2024 to 2034
Figure 167: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 168: East Asia Market Attractiveness by Country, 2024 to 2034
Figure 169: Middle East and Africa Market Value (US$ Million) by Drug Type, 2024 to 2034
Figure 170: Middle East and Africa Market Value (US$ Million) by Indication, 2024 to 2034
Figure 171: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034
Figure 172: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034
Figure 173: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034
Figure 174: Middle East and Africa Market Volume (Unit Pack) Analysis by Country, 2019 to 2034
Figure 175: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034
Figure 176: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034
Figure 177: Middle East and Africa Market Value (US$ Million) Analysis by Drug Type, 2019 to 2034
Figure 178: Middle East and Africa Market Volume (Unit Pack) Analysis by Drug Type, 2019 to 2034
Figure 179: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Type, 2024 to 2034
Figure 180: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Type, 2024 to 2034
Figure 181: Middle East and Africa Market Value (US$ Million) Analysis by Indication, 2019 to 2034
Figure 182: Middle East and Africa Market Volume (Unit Pack) Analysis by Indication, 2019 to 2034
Figure 183: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication, 2024 to 2034
Figure 184: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication, 2024 to 2034
Figure 185: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034
Figure 186: Middle East and Africa Market Volume (Unit Pack) Analysis by Distribution Channel, 2019 to 2034
Figure 187: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034
Figure 188: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034
Figure 189: Middle East and Africa Market Attractiveness by Drug Type, 2024 to 2034
Figure 190: Middle East and Africa Market Attractiveness by Indication, 2024 to 2034
Figure 191: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034
Figure 192: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
The PARP inhibitor market is projected to expand at a CAGR of 8.70% between 2024 and 2034.
The olaparib drug type segment dominates the industry.
Some leading PARP inhibitor manufacturers are AstraZeneca, GlaxoSmithKline, Merck Co. & Inc.
The PARP inhibitor market is anticipated to surpass USD 16.15 billion by 2034.
Growing awareness, targeted treatment effectiveness, and a rise in specific cancers are fueling the demand for PARP inhibitors.
Explore Similar Insights
PARP Inhibitor Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
